Director
and access,
Erik Schropp, a Dutch citizen is CEO of C&P Investors, a Director of Draupnir Holding BV and of PolyPeptide Group. Previously, Mr. Schropp held various senior finance functions in the pharmaceutical industry and is currently Board Director of various privately held companies in life sciences and gene therapy in addition to Esperante. He holds a Master’s degree in Economics & Tax from the Erasmus University Rotterdam, The Netherlands.